Share Article
SANTA MONICA, Calif., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that members of the Company's management team will participate in three upcoming conferences in November 2014:
- Credit Suisse 2014 Annual Healthcare Conference
Wednesday, November 12, 2014, at 3:00pm Local Time Arizona Biltmore, Phoenix, Arizona Presenter: Arie Belldegrun, MD, FACS, Kite Pharma's Chairman, President and Chief Executive Officer
- Stifel 2014 Healthcare Conference
Tuesday, November 18, 2014, at 3:35pm Local Time The New York Palace Hotel, New York, New York Presenter: David Chang, MD, PhD, Kite's Executive Vice President, Research and Development, and Chief Medical Officer
- Jefferies 2014 Global Healthcare Conference
Thursday, November 20, 2014, at 10:40am Local Time Waldorf Hilton, London, United Kingdom Presenter: Arie Belldegrun, MD, FACS, Chairman, President and Chief Executive Officer
About Kite Pharma, Inc.
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT™ designed to restore the immune system's ability to recognize and eradicate tumors. In partnership with the NCI Surgery Branch through a Cooperative Research and Development Agreement (CRADA), Kite is advancing a pipeline of proprietary eACT™ product candidates, both CAR (chimeric antigen receptor) and TCR (T cell receptor) products, directed to a wide range of cancer indications. Kite is based in Santa Monica, CA. For more information on Kite Pharma, please visit www.kitepharma.com.
CONTACT: Kite Pharma
Cynthia M. Butitta
Chief Financial Officer and Chief Operating Officer
310-824-9999
For Media: Justin Jackson
For Investor Inquiries: Kimberly Minarovich
Burns McClellan
212-213-0006
jjackson@burnsmc.com
kminarovich@burnsmc.com
Other News
Some of the content on this page is not intended for users outside the U.S.